Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.

Bottero V, Santiago JA, Potashkin JA.

J Parkinsons Dis. 2018;8(4):529-537. doi: 10.3233/JPD-181391.

PMID:
30248063
2.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

PMID:
30111645
3.

Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program.

Santiago JA, Bottero V, Potashkin JA.

Front Aging Neurosci. 2018 May 29;10:157. doi: 10.3389/fnagi.2018.00157. eCollection 2018.

4.

Biological and Clinical Implications of Comorbidities in Parkinson's Disease.

Santiago JA, Bottero V, Potashkin JA.

Front Aging Neurosci. 2017 Dec 4;9:394. doi: 10.3389/fnagi.2017.00394. eCollection 2017. Review.

5.

Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.

Santiago JA, Potashkin JA.

J Parkinsons Dis. 2017;7(4):653-660. doi: 10.3233/JPD-171155.

PMID:
28922168
6.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

7.

Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology.

Santiago JA, Bottero V, Potashkin JA.

Front Aging Neurosci. 2017 May 29;9:166. doi: 10.3389/fnagi.2017.00166. eCollection 2017.

8.

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson' Disease.

Santiago JA, Potashkin JA.

Front Aging Neurosci. 2017 Mar 29;9:73. doi: 10.3389/fnagi.2017.00073. eCollection 2017.

9.
10.

Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.

Santiago JA, Potashkin JA.

PLoS One. 2015 Nov 13;10(11):e0142582. doi: 10.1371/journal.pone.0142582. eCollection 2015.

11.

Reply to Liu et al.: HNF4A and PTBP1 expression in the brain of neurodegenerative disease patients.

Santiago JA, Potashkin JA.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E3976. doi: 10.1073/pnas.1510113112. Epub 2015 Jun 29. No abstract available.

12.

Reply to Toker and Pavlidis: Blood biomarkers for Parkinson's disease.

Santiago JA, Potashkin JA.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):E3638. doi: 10.1073/pnas.1508415112. Epub 2015 Jun 23. No abstract available.

13.

Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.

Santiago JA, Potashkin JA.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2257-62. doi: 10.1073/pnas.1423573112. Epub 2015 Feb 2.

14.

A network approach to clinical intervention in neurodegenerative diseases.

Santiago JA, Potashkin JA.

Trends Mol Med. 2014 Dec;20(12):694-703. doi: 10.1016/j.molmed.2014.10.002. Epub 2014 Oct 30. Review.

PMID:
25455073
15.

Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.

Santiago JA, Scherzer CR, Potashkin JA.

PLoS One. 2014 Oct 3;9(10):e109042. doi: 10.1371/journal.pone.0109042. eCollection 2014.

16.

System-based approaches to decode the molecular links in Parkinson's disease and diabetes.

Santiago JA, Potashkin JA.

Neurobiol Dis. 2014 Dec;72 Pt A:84-91. doi: 10.1016/j.nbd.2014.03.019. Epub 2014 Apr 6. Review.

PMID:
24718034
17.

The emerging role of nutrition in Parkinson's disease.

Seidl SE, Santiago JA, Bilyk H, Potashkin JA.

Front Aging Neurosci. 2014 Mar 7;6:36. doi: 10.3389/fnagi.2014.00036. eCollection 2014. Review.

18.

Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes.

Santiago JA, Potashkin JA.

PLoS One. 2013 Dec 20;8(12):e83940. doi: 10.1371/journal.pone.0083940. eCollection 2013.

19.

Current Challenges Towards the Development of a Blood Test for Parkinson's Disease.

Santiago JA, Potashkin JA.

Diagnostics (Basel). 2014 Oct 22;4(4):153-64. doi: 10.3390/diagnostics4040153. Review.

20.

A network approach to diagnostic biomarkers in progressive supranuclear palsy.

Santiago JA, Potashkin JA.

Mov Disord. 2014 Apr;29(4):550-5. doi: 10.1002/mds.25761. Epub 2013 Dec 17.

PMID:
24347522
21.

Specific splice variants are associated with Parkinson's disease.

Santiago JA, Scherzer CR; Harvard Biomarker Study, Potashkin JA.

Mov Disord. 2013 Oct;28(12):1724-7. doi: 10.1002/mds.25635. Epub 2013 Sep 20.

22.

Shared dysregulated pathways lead to Parkinson's disease and diabetes.

Santiago JA, Potashkin JA.

Trends Mol Med. 2013 Mar;19(3):176-86. doi: 10.1016/j.molmed.2013.01.002. Epub 2013 Jan 31. Review.

PMID:
23375873
23.

Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.

Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA.

PLoS One. 2012;7(8):e43595. doi: 10.1371/journal.pone.0043595. Epub 2012 Aug 27.

24.

The promise of neuroprotective agents in Parkinson's disease.

Seidl SE, Potashkin JA.

Front Neurol. 2011 Nov 21;2:68. doi: 10.3389/fneur.2011.00068. eCollection 2011. Erratum in: Front Neurol. 2013;7:69.

25.

The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment.

Wentz-Hunter KK, Potashkin JA.

Mol Biol Int. 2011;2011:839872. doi: 10.4061/2011/839872. Epub 2011 Apr 6.

26.

Limitations of animal models of Parkinson's disease.

Potashkin JA, Blume SR, Runkle NK.

Parkinsons Dis. 2010 Dec 20;2011:658083. doi: 10.4061/2011/658083.

27.
28.

Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S112-5. doi: 10.1016/j.parkreldis.2008.04.012. Epub 2008 Jun 27. Review.

29.

MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9.

Potashkin JA, Kang UJ, Loomis PA, Jodelka FM, Ding Y, Meredith GE.

Brain Res. 2007 Nov 28;1182:1-10. Epub 2007 Sep 14.

PMID:
17936734
30.

Regulation of retention of FosB intron 4 by PTB.

Marinescu V, Loomis PA, Ehmann S, Beales M, Potashkin JA.

PLoS One. 2007 Sep 5;2(9):e828.

31.

Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.

Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, Abdul-Karim FW, Gorodeski GI.

Gynecol Oncol. 2007 Jul;106(1):233-43. Epub 2007 May 4.

32.

Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies.

Alibhai IN, Green TA, Potashkin JA, Nestler EJ.

Brain Res. 2007 Apr 27;1143:22-33. Epub 2007 Jan 27.

33.

The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease.

Potashkin JA, Meredith GE.

Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):144-51. Review.

PMID:
16487048
34.

The genome sequence of Schizosaccharomyces pombe.

Wood V, Gwilliam R, Rajandream MA, Lyne M, Lyne R, Stewart A, Sgouros J, Peat N, Hayles J, Baker S, Basham D, Bowman S, Brooks K, Brown D, Brown S, Chillingworth T, Churcher C, Collins M, Connor R, Cronin A, Davis P, Feltwell T, Fraser A, Gentles S, Goble A, Hamlin N, Harris D, Hidalgo J, Hodgson G, Holroyd S, Hornsby T, Howarth S, Huckle EJ, Hunt S, Jagels K, James K, Jones L, Jones M, Leather S, McDonald S, McLean J, Mooney P, Moule S, Mungall K, Murphy L, Niblett D, Odell C, Oliver K, O'Neil S, Pearson D, Quail MA, Rabbinowitsch E, Rutherford K, Rutter S, Saunders D, Seeger K, Sharp S, Skelton J, Simmonds M, Squares R, Squares S, Stevens K, Taylor K, Taylor RG, Tivey A, Walsh S, Warren T, Whitehead S, Woodward J, Volckaert G, Aert R, Robben J, Grymonprez B, Weltjens I, Vanstreels E, Rieger M, Schäfer M, Müller-Auer S, Gabel C, Fuchs M, Düsterhöft A, Fritzc C, Holzer E, Moestl D, Hilbert H, Borzym K, Langer I, Beck A, Lehrach H, Reinhardt R, Pohl TM, Eger P, Zimmermann W, Wedler H, Wambutt R, Purnelle B, Goffeau A, Cadieu E, Dréano S, Gloux S, Lelaure V, Mottier S, Galibert F, Aves SJ, Xiang Z, Hunt C, Moore K, Hurst SM, Lucas M, Rochet M, Gaillardin C, Tallada VA, Garzon A, Thode G, Daga RR, Cruzado L, Jimenez J, Sánchez M, del Rey F, Benito J, Domínguez A, Revuelta JL, Moreno S, Armstrong J, Forsburg SL, Cerutti L, Lowe T, McCombie WR, Paulsen I, Potashkin J, Shpakovski GV, Ussery D, Barrell BG, Nurse P.

Nature. 2002 Feb 21;415(6874):871-80. Erratum in: Nature 2003 Jan 2;421(6918):94. Cerrutti L [corrected to Cerutti L].

PMID:
11859360
35.

Conserved Wat1/Pop3 WD-repeat protein of fission yeast secures genome stability through microtubule integrity and may be involved in mRNA maturation.

Ochotorena IL, Hirata D, Kominami K, Potashkin J, Sahin F, Wentz-Hunter K, Gould KL, Sato K, Yoshida Y, Vardy L, Toda T.

J Cell Sci. 2001 Aug;114(Pt 16):2911-20.

36.

Analysis of the splicing machinery in fission yeast: a comparison with budding yeast and mammals.

Käufer NF, Potashkin J.

Nucleic Acids Res. 2000 Aug 15;28(16):3003-10. Review.

37.

Mutations in the large subunit of U2AF disrupt pre-mRNA splicing, cell cycle progression and nuclear structure.

Beales M, Flay N, McKinney R, Habara Y, Ohshima Y, Tani T, Potashkin J.

Yeast. 2000 Aug;16(11):1001-13.

38.

Cell-division-cycle defects associated with fission yeast pre-mRNA splicing mutants.

Potashkin J, Kim D, Fons M, Humphrey T, Frendewey D.

Curr Genet. 1998 Sep;34(3):153-63.

PMID:
9745017
39.

A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site.

Gozani O, Potashkin J, Reed R.

Mol Cell Biol. 1998 Aug;18(8):4752-60.

40.

Molecular characterization of a novel fission yeast gene spUAP2 that interacts with the splicing factor spU2AF59.

McKinney R, Wentz-Hunter K, Schmidt H, Potashkin J.

Curr Genet. 1997 Nov;32(5):323-30.

PMID:
9371883
41.

BTF3 is evolutionarily conserved in fission yeast.

Potashkin J, Wentz-Hunter K, Callaci J.

Biochim Biophys Acta. 1996 Sep 11;1308(3):182-4.

PMID:
8809106
42.

The small subunit of the splicing factor U2AF is conserved in fission yeast.

Wentz-Hunter K, Potashkin J.

Nucleic Acids Res. 1996 May 15;24(10):1849-54.

43.

The evolutionary conservation of the splicing apparatus between fission yeast and man.

Wentz-Hunter K, Potashkin J.

Nucleic Acids Symp Ser. 1995;(33):226-8. Review.

PMID:
8643378
44.

U2AF homolog required for splicing in vivo.

Potashkin J, Naik K, Wentz-Hunter K.

Science. 1993 Oct 22;262(5133):573-5.

PMID:
8211184
45.

Differential distribution of factors involved in pre-mRNA processing in the yeast cell nucleus.

Potashkin JA, Derby RJ, Spector DL.

Mol Cell Biol. 1990 Jul;10(7):3524-34.

46.

Schizosaccharomyces U6 genes have a sequence within their introns that matches the B box consensus of tRNA internal promoters.

Frendewey D, Barta I, Gillespie M, Potashkin J.

Nucleic Acids Res. 1990 Apr 25;18(8):2025-32.

48.

Splicing of the U6 RNA precursor is impaired in fission yeast pre-mRNA splicing mutants.

Potashkin J, Frendewey D.

Nucleic Acids Res. 1989 Oct 11;17(19):7821-31.

49.

Pre-mRNA splicing mutants of Schizosaccharomyces pombe.

Potashkin J, Li R, Frendewey D.

EMBO J. 1989 Feb;8(2):551-9.

50.

Supplemental Content

Loading ...
Support Center